Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer

키워드

참고문헌 (30)

1. Thompson AM, "Neoadjuvant treatment of breast cancer", Ann Oncol, 23(Suppl 10), pp.x231~x236 (2012)
2. Ignatiadis M, "St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists", Ann Oncol, 26, pp.1519~1520 (2015)
3. Senkus E, "Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 26(Suppl 5), pp.v8~v30 (2015)
4. Lee SH, "The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer", Am J Surg, 186, pp.348~350 (2003)
5. Makris A, "Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study", Breast Cancer Res Treat, 53, pp.51~59 (1999)
6. Chen S, "Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer", Ann Surg Oncol, 19, pp.3002~3011 (2012)
7. Zhang N, "The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis", Cancer Invest, 29, pp.594~598 (2011)
8. Siew Kuan Lim, "Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome", Cancer Research and Treatment, 48(1), pp.133~141 (2016), 대한암학회[DOI]
9. Hirata T, "Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer", Br J Cancer, 101, pp.1529~1536 (2009)
10. Jin X, "Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study", Oncotarget, 6, pp.9600~9611 (2015)
11. Gahlaut R, "Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER", PR and HER2 expression: implications for the practising oncologist, 2016, pp.60, 40~48
12. Kasami M, "Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy", Breast, 17, pp.523~527 (2008)
13. Tacca O, "Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy", Oncologist, 12, pp.636~643 (2007)
14. Tan QX, "Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients", Int J Clin Exp Pathol, 7, pp.4086~4094 (2014)
15. Ogston KN, "A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival", Breast, 12, pp.320~327 (2003)
16. Symmans WF, "Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy", J Clin Oncol, 25, pp.4414~4422 (2007)
17. Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis", Mod Pathol, 11, pp.155~168 (1998)
18. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
19. Lee HJ, "HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer", Am J Clin Pathol, 142, pp.755~766 (2014)
20. Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
21. Reddy OL, "Breast cancer biomarker changes after neoadjuvant chemotherapy: a single institution experience and literature review", Clin Oncol, 2, pp.1245~ (2017)
22. Zhou X, "Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration", Oncotarget, 6, pp.36894~36902 (2015)
23. Xian Z, "Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?", Hum Pathol, 62, pp.215~221 (2017)
24. Wu JY, "Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy", Mol Clin Oncol, 2, pp.997~1002 (2014)
25. Mittendorf EA, "Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes", Clin Cancer Res, 15, pp.7381~7388 (2009)
26. Cui X, "Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy", J Clin Oncol, 23, pp.7721~7735 (2005)
27. Thakkar JP, "A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative", Oncologist, 16, pp.276~285 (2011)
28. Balleine RL, "Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women", Br J Cancer, 79, pp.1564~1571 (1999)
29. Chen X, "Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer", BMC Cancer, 13, pp.390~ (2013)
30. Park SY, "The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer", Am J Surg, 197, pp.266~269 (2009)

관련 논문AI추천